PMV Pharmaceuticals, Inc. (PMVP)
Largest Insider Buys in Sector
PMVP Stock Price History Chart
PMVP Stock Performance
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and …
Insider Activity of PMV Pharmaceuticals, Inc.
Over the last 12 months, insiders at PMV Pharmaceuticals, Inc. have bought $0 and sold $210,963 worth of PMV Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at PMV Pharmaceuticals, Inc. have bought $106.6M and sold $18.57M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,900,000 shares for transaction amount of $34.2M was made by RA CAPITAL MANAGEMENT, L.P. (10 percent owner) on 2020‑09‑29.
List of Insider Buy and Sell Transactions, PMV Pharmaceuticals, Inc.
| 2024-09-11 | Sale | Chief Development Officer | 7,218 0.0141% | $1.50 | $10,853 | -0.90% | ||
| 2024-09-11 | Sale | Chief Financial Officer | 2,891 0.0057% | $1.50 | $4,347 | -0.90% | ||
| 2023-11-22 | Sale | 10 percent owner | 87,786 0.1816% | $2.23 | $195,763 | -23.70% | ||
| 2023-09-15 | Sale | Chief Medical Officer | 6,291 0.0128% | $6.62 | $41,646 | -73.47% | ||
| 2023-09-15 | Sale | Chief Development Officer | 4,104 0.0084% | $6.62 | $27,168 | -73.47% | ||
| 2022-05-26 | Sale | 26,253 0.0695% | $15.93 | $418,210 | -25.36% | |||
| 2022-03-29 | Sale | 365,000 0.7867% | $21.52 | $7.85M | -45.86% | |||
| 2021-10-06 | Sale | director | 800 0.0019% | $30.15 | $24,120 | -43.26% | ||
| 2021-10-04 | Sale | director | 100 0.0002% | $30.08 | $3,008 | -43.75% | ||
| 2021-10-01 | Sale | director | 11,541 0.0255% | $30.10 | $347,384 | -46.13% | ||
| 2021-09-30 | Sale | director | 2,978 0.0066% | $30.03 | $89,429 | -45.30% | ||
| 2021-09-29 | Sale | director | 5,708 0.0127% | $30.04 | $171,468 | -45.33% | ||
| 2021-09-27 | Sale | director | 1,753 0.004% | $30.11 | $52,783 | -44.51% | ||
| 2021-09-22 | Sale | director | 100 0.0002% | $30.00 | $3,000 | -41.71% | ||
| 2021-09-22 | Sale | director | 3,500 0.0082% | $30.00 | $105,000 | -41.71% | ||
| 2021-09-17 | Sale | director | 711 0.0016% | $30.03 | $21,351 | -42.79% | ||
| 2021-09-13 | Sale | director | 13,272 0.0311% | $30.20 | $400,814 | -40.29% | ||
| 2021-09-10 | Sale | director | 43,227 0.0948% | $30.51 | $1.32M | -44.58% | ||
| 2021-09-09 | Sale | director | 14,329 0.0332% | $30.31 | $434,312 | -40.96% | ||
| 2021-09-09 | Sale | Chief Medical Officer | 100 0.0002% | $30.25 | $3,025 | -40.96% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 10 percent owner | 0 0% | $1.62 | 1 | 1 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 1710265 3.305% | $1.62 | 1 | 0 | <0.0001% |
| Boxer Capital, LLC | 950000 1.8359% | $1.62 | 1 | 0 | <0.0001% | |
| Thompson Peter A. | 475000 0.9179% | $1.62 | 1 | 0 | <0.0001% | |
| ORONSKY ARNOLD L | 55555 0.1074% | $1.62 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| OrbiMed | $11.01M | 12.59 | 6.48M | 0% | +$0 | 0.09 | |
| Arrowmark Colorado Holdings Llc | $5.44M | 6.22 | 3.2M | +17.86% | +$823,842.07 | 0.01 | |
| BlackRock | $5.29M | 6.05 | 3.11M | -3.7% | -$203,129.59 | <0.0001 | |
| Euclidean Capital Llc | $4.47M | 5.11 | 2.63M | 0% | +$0 | 0.58 | |
| The Vanguard Group | $4.17M | 4.77 | 2.45M | +1.95% | +$79,566.81 | <0.0001 |